{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:14:21Z","timestamp":1765728861492,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor. Factor VIII deficiency is responsible for hemophilia A while factor IX deficiency is responsible for hemophilia B. As per the 2020 annual global survey by the World Federation of Hemophilia, only 1828 Thai hemophiliacs have been registered to the national healthcare system. The reason for the low number is the underdiagnosis which is a major concern in the real-world practice among Asian countries. In Thailand, most hemophiliacs are diagnosed by general practitioners, pediatricians or internists at rural hospitals and are referred to hemophilia specialists at the Hemophilia Treatment Centers (HTCs). Despite the challenges pertaining to infrastructure and cost of treatment, Thailand has progressed substantially in providing the required hemophilia care, as evidenced by an evolution in acquiring and sharing knowledge as well as collaborative efforts among multiple stakeholders over the past three decades. In this letter-to-the-editor, the authors have summarized the practices for and challenges faced with hemophilia management in Thailand.<\/jats:p>","DOI":"10.1186\/s13023-023-02718-1","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T09:09:40Z","timestamp":1683709780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Practices and challenges for hemophilia management under resource constraints in Thailand"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-0867","authenticated-orcid":false,"given":"Chatphatai","family":"Moonla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-3482","authenticated-orcid":false,"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-0118","authenticated-orcid":false,"given":"Bunchoo","family":"Pongtanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-9351","authenticated-orcid":false,"given":"Bundarika","family":"Suwanawiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5635-1238","authenticated-orcid":false,"given":"Chanchai","family":"Traivaree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-3443","authenticated-orcid":false,"given":"Rungrote","family":"Natesirinilkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-5476","authenticated-orcid":false,"given":"Nongnuch","family":"Sirachainan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-3485","authenticated-orcid":false,"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"issue":"Suppl 6","key":"2718_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"3","key":"2718_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13998","volume":"26","author":"JM Soucie","year":"2020","unstructured":"Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487\u201393.","journal-title":"Haemophilia"},{"key":"2718_CR3","unstructured":"World Federation of Hemophilia. Report on the Annual Global Survey 2020 [Internet]. Montreal: World Federation of Hemophilia; 2021. [cited 2023 April 3]. https:\/\/www1.wfh.org\/publications\/files\/pdf-2045.pdf"},{"issue":"1","key":"2718_CR4","first-page":"19","volume":"140","author":"A Kar","year":"2014","unstructured":"Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social costs of haemophilia in India. Indian J Med Res. 2014;140(1):19\u201331.","journal-title":"Indian J Med Res"},{"issue":"6","key":"2718_CR5","first-page":"535","volume":"16","author":"G Benson","year":"2018","unstructured":"Benson G, Auerswald G, Dolan G, Duffy A, Hermans C, Ljung R, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16(6):535\u201344.","journal-title":"Blood Transfus"},{"issue":"5","key":"2718_CR6","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1111\/hae.13601","volume":"24","author":"A Chuansumrit","year":"2018","unstructured":"Chuansumrit A, Sosothikul D, Natesirinilkul R, Lektrakul Y, Charoonruangrit U, Factor VIII Study Group. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society. Haemophilia. 2018;24(5):e387\u201390.","journal-title":"Haemophilia"},{"issue":"1","key":"2718_CR7","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1111\/hae.14215","volume":"27","author":"R Liesner","year":"2021","unstructured":"Liesner R, Andersson NG, Frisk T, Santagostino E, Schulz M, Young L, et al. Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study. Haemophilia. 2021;27(1):e60\u20138.","journal-title":"Haemophilia"},{"issue":"1","key":"2718_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hae.14707","volume":"29","author":"A Chuansumrit","year":"2023","unstructured":"Chuansumrit A, Sirachainan N, Jaovisidha S, Jiravichitchai T, Kadegasem P, Kempka K, et al. Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: a case series report. Haemophilia. 2023;29(1):382\u20135.","journal-title":"Haemophilia"},{"issue":"1","key":"2718_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/hae.14194","volume":"27","author":"A Chuansumrit","year":"2021","unstructured":"Chuansumrit A, Sirachainan N, Natesirinilkul R, Srikala K, Masaya-Anon N, Haemophilia Inhibitor Study Group. Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes. Haemophilia. 2021;27(1):69\u201380.","journal-title":"Haemophilia"},{"key":"2718_CR10","doi-asserted-by":"publisher","first-page":"711973","DOI":"10.3389\/fmed.2021.711973","volume":"8","author":"N Dirzu","year":"2021","unstructured":"Dirzu N, Hotea I, Jitaru C, Brinza M, Urian L, Peters MC, et al. Mobile health technology for the personalized therapy of hemophilia. Front Med (Lausanne). 2021;8:711973.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"2718_CR11","doi-asserted-by":"publisher","first-page":"e12695","DOI":"10.1002\/rth2.12695","volume":"6","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Yamaguti-Hayakawa GG. Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost. 2022;6(3):e12695.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2718_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(4):310\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"2718_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2022016571","volume":"141","author":"C Ay","year":"2023","unstructured":"Ay C, Kovacevic KD, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas C, et al. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. Blood. 2023;141(10):1147\u201358.","journal-title":"Blood"},{"issue":"2","key":"2718_CR14","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/hae.14496","volume":"28","author":"A Chuansumrit","year":"2022","unstructured":"Chuansumrit A, Youttananukorn W, Sirachainan N, Natesirinilkul R, Ruchutrakool T. Direct transfer of data of people with haemophilia from the Thai Haemophilia Treatment Centre Registry to the World Bleeding Disorders Registry of the World Federation of Hemophilia. Haemophilia. 2022;28(2):e68\u201370.","journal-title":"Haemophilia"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02718-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02718-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02718-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T09:14:28Z","timestamp":1683710068000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02718-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02718-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"All the authors participated in the advisory board on whose basis the publication was developed. Authors C.M. and D.S. received honorarium from Pfizer (Thailand) Ltd. to participate in the advisory board. C.M. additionally reported receiving grants from Pfizer (Thailand) Ltd., Novo Nordisk Pharma (Thailand) Ltd., and Rachadapiseksompotch Fund, Chulalongkorn University outside the submitted work. All other authors stated that they had no interests which might be perceived as posing a conflict or bias.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}